45 results about "Isoprostaglandin E1" patented technology

The invention relates to a method for preparing a prostaglandin E1 lipid microsphere injection of a charging non-homogeneous phase (comprising a water phase, an oil/water interfacial film phase and an oil phase) dispersion system, of which the surface of the lipid microsphere can be charged with positive electricity or negative electricity. The prostaglandin E1 is alprostadil, of which the chemical structure comprises a basic skeleton of 20-carbon fatty acid with a 5-carbon ring and two side chains, wherein one side chain is provided with a hydrophilic carboxylic acid group, so that the prostaglandin E1 has the characteristic of light surface activity action. By utilizing the characteristic, and according to the formula and the preparation process provided in the invention, the prostaglandin E1 has an unique drug-carrying mode in a solution of lipid microsphere with the non-homogeneous phase dispersion system, and the prepared lipid microsphere injection is fundamentally different from an alprostadil injection(Kaishi, and is prepared by adopting the technology of the Japanese business corporation LTT Bio-Pharma Co., Ltd. already sold in markets, and the difference lies in that the drug-carrying mode is completely different, the content of degradation products in the preparation such as impurities is more than 50 percent lower than that of in the Kaishi, so that the prostaglandin E1 lipid microsphere injection and the alprostadil injection are fundamentally different. The invention relates to a method for preparing the prostaglandin E1 lipid microsphere injection and the drug-carrying characteristics thereof in a three-phase system; in the formula, 0.0001 to 0.1 weight portion of prostaglandin E1 is used as a drug, the prostaglandin E1 is added with auxiliary materials for medical purpose to prepare the prostaglandin E1 lipid microsphere injection, and the auxiliary materials for medical purpose comprises the following materials in portion by weight: 5 to 20.

The invention relates to prostaglandin microemulsion-gel preparation and a preparation method thereof. The preparation comprises prostaglandin E1 or the derivative thereof, oil, emulsifier, assistant for emulsifying agent, gel substrate and water, and also possibly comprises a permeation accelerator, a preparation stabilizer, an antioxidant and antiseptics. The preparation has the advantages of good percutaneous permeability, no stimulation to skin and mucous membrane, simple preparation technique and stable quality, the preparation can be used for treating diseases such as ulcer of limbs caused by erectile dysfunction and chronic arterial occlusion and rest pain of limbs caused by microcirculatory disturbance.

The invention provides a serum-free culture medium used for full-suspension culture of MDCK (Madin Darby Canine Kidney) cells. The culture medium is prepared from a DMEM/F12 culture medium containing 5g/L of NaCl and the following components: sodium stannite, recombinant human epidermal growth factors, hydrocortisone, recombinant full-chain insulin, prostaglandin E1, human transferrin, thyroxine (T3), vitamin E, cholesterol, ethanol amine, beta-mercaptoethanol, Tween-80, Hypep1510, recombinant human serum albumin ACF and mannitol. With the adoption of the culture medium provided by the invention, the full-suspension culture of the MDCK cells can be carried out very well under the condition that serum is not added; after the MDCK cells are continuously cultured for 20 generations, the average proliferation concentration of the MDCK cells is 2.308*10<6>/mL, the average cell viability is 97.4 percent and the average doubling time is 34.48 hours, so that the serum-free culture medium provides technical supports for developing influenza vaccines of cell matrixes of mammals in China.

The present invention provides a prostaglandin E1 liposome fronen dry powder injection and its production process. It is mainly characterized by that it uses soya lectithin and cholesterol to cover high-purity prostaglandin E1 so as to make them into freeze-dried powder injection. Said process can greatly raise stability of the finished product in production, can prolong expiry date, and can reduce side reaction.

A compound medicine containing kurarinol, prostaglandic E1 and aspirin is prepared through including the kurarinol and prostaglandin E1 by 6-0-malto-beta-cyclodextrin, mixing, adding others, and preparing the freeze dried powder injection. It can be used for treating cancers, cardiovascular and cerebrovascular diseases and hepatitis. Its advantages are sure curative effect, and no toxic by-effect.

A method for treating irritable bowel syndrome in a mammalian subject includes administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E₁ or 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E₁, or a salt, ether, ester or amide thereof, to the subject. A method for treating abdominal discomfort associated with irritable bowel syndrome in a mammalian subject includes administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E₁ or 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E₁, or a salt, ether, ester or amide thereof, to the subject.

The invention discloses a method for measuring prostaglandin E1 and/or prostaglandin A1 in alprostadil fat emulsion injection, which comprises the following steps: (1) ultrasonically processing the alprostadil fat emulsion injection, obtaining an alprostadil solution of which the fat phase is removed; and (2) performing high performance liquid chromatography measurement to the alprostadil solution of which the fat phase is removed, obtaining the content of the prostaglandin E1 and/or prostaglandin A1, wherein the conditions of the high performance liquid chromatography measurement are as follows: stationary phase: octadecyl ether-bonded monolithic silica is filling agent, mobile phase: the ratio of phosphate buffer to acetonitrile is equal to 1-6:1, and the detection wavelength is 278 nm. The method can accurately measure the alprostadil and the degradation products thereof in the alprostadil fat emulsion injection.

Disclosed is a fat emulsion containing a compound having prostaglandin E1 activity, which fat emulsion is hermetically sealed in a glass container and then heat sterilized. The residual amount of prostaglandin E1 activity after 16-month storage at 5 DEG C is not less than 65% but not more than 100% of the prostaglandin E1 activity at the beginning of storage.

The present invention discloses a compound injection in absolut ethyl alcohol or compound powdered injection preparation of prostaglandin E1, prostaglandin E1 potassium salt, prostaglandin E1 sodium salt or prostaglandin A1 and prostaglandin B1. The compound preparation is used in preventing and treating AIDS and abstaining from drugs. It has unique recipe, complementary components, determined curative effect and less toxic side effect.

A method of treating or preventing adhesion formation during or following a surgical procedure comprising administering to a patient in need thereof at least one medicament selected from the group consisting of potassium channels; modulators of macrophage activation and leucocyte attraction through cytokines, or their inhibitors, antibodies or inhibitors blocking the effect of VEGF expression; prostaglandin E1; free radical scavengers, lipid peroxysomes; pregnatrienes; calcium antagonists; hypoxia; acidosis; MP; dopamine; and ATP-MgCl₂, wherein the method prevents adhesion formation by preventing anoxemia.

The invention relates to a compound preparation for treating the ischemic brain damage; wherein, the active component comprises prostaglandin E1 the lithium salt; the prostaglandin E1 and the lithium salt can be mixed into the intravenous injection or infusion mixture, and the prostaglandin E1 also can be made into the intravenous injection or infusion agent, meanwhile the lithium salt can be made into the subcutaneous injection. The invention has the advantages of enabling to be used on the people needing treatment or the experiment animal, inducing the formation of the heat shock protein, protects the neuron, increasingg the resistance of the cell hypoxia, and resisting the ischemic brain damage function through the synergistic interaction of the prostaglandin E1 and the lithium salt compound preparation. The invention also has an advantage that: the application dosage of two medicines in the prostaglandin E1 and the lithium salt compound preparation are both lower than the convention dosage of the two medicine in the clinic, so as to reduce the adverse reaction and improve the curative effect. The invention provides a new compound preparation for the ischemic cerebral apoplexy.

The invention discloses a derivative of prostaglandin, represented by the formula (I), the pharmaceutically acceptable salt and a preparation method thereof. In the formula, R1 is beta-D-glucosylsorbitol, beta-D-pyrane galactosyl, beta-D-pyrane xylosyl, alpha-L-pyrane rhamnoside, alpha-L-pyrane arabinose, alpha-D-pyrane mannose, alpha-D-fructofurano, beta-D-fructo ribosyl, beta-L-pyrane fucosyl, beta-D-glucosyl, beta-D-lactosyl, beta-D-cellobiose diglycosyl, and R2 is hydrogen or methyl. The invention provides a stable and long-acting derivative of prostaglandin E1 so as to adapt to treating requirement.

The invention relates to a method for preparing a compound with a structural formula (I). The compound with the formula (I) is a derivative of prostaglandin E1, and the chemical stability of the derivative is superior to that of the prostaglandin E1. The synthesis process disclosed by the invention is a complete synthesis method of the compound with the formula (I), and the method is simple and feasible.

An orally applied prostaglandin E1 in the tablet is disclosed.

The invention relates to pharmaceutical composition for treating diabetic feet caused by diabetes and acro-skin lesion and a preparation method of the pharmaceutical composition. The pharmaceutical composition is an ointment which is prepared by mixing prostaglandin E1 (PGE1) and monosialoteterahexosyl ganglioside (GM1) according to a proper proportion and adding an appropriate proportion of auxiliary materials. Experiments on animals show that the pharmaceutical composition has an ideal treatment effect on the diabetic feet caused by the diabetes and the acro-skin lesion, and is prepared into the ointment for external use and convenient to apply; an affected part is coated with the ointment directly; and the pharmaceutical composition can realize transdermal absorption, takes effect quickly, and is good in safety, clear in treatment effect, low in cost and good in adaptability of a patient.

A nasally applied powder of prostaglandin E1 is disclosed.

A pharmaceutical composition for enhancing male erectile function comprising an erectile function-enhancing amount of an insulin-like growth factor selected from the group consisting of IGF-1 (Somatmedin-C) and analogue LR3 IGF1 in admixture with a pharmaceutically-acceptable diluents or carrier. Such compositions optionally further comprise compounds selected from an androgen, particularly, testosterone and dihydrotestosterone, a vasodilator, PDE5 inhibitor and prostaglandin E1.

The invention provides a P2Y12 receptor platelet aggregation detection reagent card and a production method thereof. The P2Y12 receptor platelet aggregation detection reagent card comprises four detection channels, the first channel contains a lyophilized reagent coated with BSA and fibrinogen and contains no activators, the second channel contains a lyophilized reagent coated with the BSA and fibrinogen and also contains a platelet maximum activator iso-TRAP (thrombin receptor activating peptide), the third channel contains no lyophilized reagents, and the fourth channel contains the lyophilized reagent coated with the BSA and fibrinogen, and also contains a platelet P2Y12 receptor activator ADP (adenosine diphosphate) and a P2Y1 receptor antagonist PGE1 (prostaglandin E1). The patient'sP2Y12 receptor pathway-correlated platelet aggregation function is rapidly and effectively detected through optical nephelometry by using the detection reagent card. The card has the advantages of high sensitivity, strong specificity, easiness in operation, and suitableness for bedside fast detection, and can well predict the future thrombus or bleeding risk in patients treated with the P2Y12 receptor antagonists.

Disclosed is a therapeutic agent for ameliorating the prognosis after lower limb amputation surgery which is induced by severe peripheral arterial disease. The therapeutic agent comprises a prostaglandin E1 (PGE1) derivative shown by the formula (I) (AS-013) as an active ingredient. Preferably, the therapeutic agent takes a dosage form of a preparation for intravenous or local administration. More preferably, the preparation for injection takes a dosage form of a liposome preparation having the active ingredient AS-013 embedded in a lipid particle.

A topical composition of a semi-solid consistency suitable is provided for transdermal application of prostaglandin E1. The composition comprises prostaglandin E1, a penetration enhancer, a polysaccharide gum, a lipophilic compound, and an acidic buffer system. The penetration enhancer is an alkyl-2-(N,N-disubstituted amino)-alkanoate ester, an (N,N-disubstituted amino)-alkanol alkanoate, or a mixture of these. The lipophilic compound may be an aliphatic C1 to C8 alcohol, an aliphatic C8 to C30 ester, or a mixture of these. The composition includes a buffer system capable of providing a buffered pH value for said composition in the range of about 3 to about 7.4.

The invention provides methods of treating erectile dysfunction comprising the step of placing within the fossa navicularis of the patient an effective erection-inducing amount of a prostaglandin E1 composition of a semi-solid consistency. The composition comprises prostaglandin E1, a penetration enhancer, a polysaccharide gum, a lipophilic compound, and an acidic buffer system. The penetration enhancer is an alkyl-2-(N,N-disubstituted amino)-alkanoate ester, an (N,N-disubstituted amino)-alkanol alkanoate, or a mixture of these. The lipophilic compound may be an aliphatic C1 to C8 alcohol, an aliphatic C8 to C30 ester, or a mixture of these. The composition includes a buffer system capable of providing a buffered pH value for said composition in the range of about 3 to about 7.4.